We are a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential,yet historically undruggable, protein targets driving human disease. We leverage our proprietary platform to pioneer a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines. Our principal executive offices are located in Cambridge, MA.
